BR0108609A - Anticorpo com especificidade pelo câncer de cólon - Google Patents

Anticorpo com especificidade pelo câncer de cólon

Info

Publication number
BR0108609A
BR0108609A BR0108609-0A BR0108609A BR0108609A BR 0108609 A BR0108609 A BR 0108609A BR 0108609 A BR0108609 A BR 0108609A BR 0108609 A BR0108609 A BR 0108609A
Authority
BR
Brazil
Prior art keywords
target
colon cancer
specific antibody
cancer specific
binds
Prior art date
Application number
BR0108609-0A
Other languages
English (en)
Inventor
Thomas N Brodin
Pia J Karlstrom
Bo H K Nilson
Lennart G Ohlsson
M Jesper Tordsson
Original Assignee
Active Biotech Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Active Biotech Ab filed Critical Active Biotech Ab
Publication of BR0108609A publication Critical patent/BR0108609A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57535—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the large intestine, e.g. colon, rectum or anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6863—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from stomach or intestines cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3046—Stomach, Intestines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

"ANTICORPO COM ESPECIFICIDADE PELO CâNCER DE CóLON". Uma estrutura de ligação a qual se liga em e/ou à superfície de células de tumor; uma estrutura alvo visualizada e/ou expressa em e/ou sobre a superfície de células de tumor; uma estrutura de ligação que reconhece e bloqueia a referida estrutura alvo; uma substância que se liga ou bloqueia a expressão da referida estrutura alvo; composições farmacêuticas compreendendo a referida estrutura de ligação, estruturas alvo ou substância como princípios ativos; composições de vacina compreendendo as referidas estruturas alvo como princípios ativos; um método para seleção por fago; e métodos de diagnose e prognose in vitro e in vivo e de tratamento de doenças malignas humanas compreendendo o uso das matérias em questão acima, são descritos.
BR0108609-0A 2000-02-24 2001-02-23 Anticorpo com especificidade pelo câncer de cólon BR0108609A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE0000597A SE0000597D0 (sv) 2000-02-24 2000-02-24 Novel antibody
PCT/SE2001/000395 WO2001062286A1 (en) 2000-02-24 2001-02-23 Novel antibody with specificity for colon cancer

Publications (1)

Publication Number Publication Date
BR0108609A true BR0108609A (pt) 2002-11-19

Family

ID=20278567

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0108609-0A BR0108609A (pt) 2000-02-24 2001-02-23 Anticorpo com especificidade pelo câncer de cólon

Country Status (22)

Country Link
US (1) US7425623B2 (pt)
EP (1) EP1257291A1 (pt)
JP (1) JP2003523213A (pt)
KR (1) KR20020079888A (pt)
CN (1) CN1406136A (pt)
AU (1) AU775876B2 (pt)
BR (1) BR0108609A (pt)
CA (1) CA2400661A1 (pt)
EE (1) EE200200473A (pt)
HK (1) HK1052648A1 (pt)
HU (1) HUP0300007A3 (pt)
IL (1) IL151325A0 (pt)
MX (1) MXPA02008315A (pt)
NO (1) NO20023670L (pt)
NZ (1) NZ520523A (pt)
PL (1) PL356386A1 (pt)
RU (1) RU2268068C2 (pt)
SE (1) SE0000597D0 (pt)
SK (1) SK11982002A3 (pt)
WO (1) WO2001062286A1 (pt)
YU (1) YU63702A (pt)
ZA (1) ZA200206039B (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003008450A1 (en) * 2001-06-12 2003-01-30 Kyogo Itoh Tumor antigen
US20030206916A1 (en) 2002-05-03 2003-11-06 Rush-Presbyterian-St. Luke's Medical Center Immunogenic peptides
CN1303105C (zh) * 2003-12-08 2007-03-07 陈志南 抗人大肠癌单克隆抗体CAb—2轻、重链可变区基因及其应用
CN101516912B (zh) * 2006-06-07 2013-10-30 生物联合公司 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
EP2048241B1 (en) * 2007-10-08 2012-07-25 Sividon Diagnostics GmbH Method employing GAPDH as molecular markers for cancer prognosis
CN105732813A (zh) * 2007-12-18 2016-07-06 生物联合公司 识别癌细胞上表达的cd-43和cea的含糖表位的抗体及其使用方法
EP2322224B1 (en) * 2008-09-01 2013-07-17 National University Corporation Nagoya University Prognosis of colon cancers
FR2945952B1 (fr) * 2009-05-27 2013-10-04 Univ Claude Bernard Lyon Anticorps anti-ck8 pour utilisation comme medicament.
CN117737190A (zh) * 2023-12-15 2024-03-22 承德医学院 一种检测结直肠癌肿瘤细胞相关微生物的方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5798257A (en) * 1990-07-09 1998-08-25 Research Corporation Technologies, Inc. Nucleic acid encoding human MTS-1 protein
US5994088A (en) * 1991-03-08 1999-11-30 Board Of Trustees Of The University Of Illinois Methods and reagents for preparing and using immunological agents specific for P-glycoprotein
SG52492A1 (en) * 1992-08-07 1998-09-28 Cytel Corp Hla binding peptides and their uses
US5972643A (en) * 1994-06-17 1999-10-26 Fred Hutchinson Cancer Research Center Isolated polynucleotide molecules encoding CTCF, a CCCTC-binding factor
WO1997002479A2 (en) * 1995-06-30 1997-01-23 Yale University Human monoclonal anti-tumor antibodies
EP0885299B1 (en) * 1996-01-08 2005-10-26 Genentech, Inc. Ob receptor and ligands
WO1998003411A1 (fr) 1996-07-18 1998-01-29 Montania Bouchon avec recipient auxiliaire et procede de realisation
JP2001512560A (ja) * 1996-10-08 2001-08-21 ユー―ビスイス ベスローテン フェンノートシャップ 標的に対し特異的な親和性を有するペプチドおよびタンパク質の選択のための方法および手段
SE9700291D0 (sv) * 1997-01-31 1997-01-31 Pharmacia & Upjohn Ab Selection method and prodcts resulting therefrom
DK0979281T3 (da) * 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
CA2302292A1 (en) * 1997-08-29 1999-03-04 Selective Genetics, Inc. Methods using phage display for selecting internalizing ligands for gene delivery
DE19739525A1 (de) * 1997-09-09 1999-09-30 Heinrich Abbrederis Die Vorrichtung T.C.Reinigungskopf ermöglicht die Reinigung, Schmierung und Konservierung von Ketten im eingebauten und ausgebauten Zustand unter minimalen Platzverhältnissen
EP0934953A2 (en) * 1997-12-03 1999-08-11 Boehringer Mannheim Corporation Complex specific antibodies, method of preparation and uses thereof
AU770952B2 (en) * 1999-03-01 2004-03-11 Genentech Inc. Antibodies for cancer therapy and diagnosis

Also Published As

Publication number Publication date
NZ520523A (en) 2004-08-27
HK1052648A1 (zh) 2003-09-26
ZA200206039B (en) 2003-07-29
WO2001062286A1 (en) 2001-08-30
AU775876B2 (en) 2004-08-19
HUP0300007A2 (en) 2003-05-28
US7425623B2 (en) 2008-09-16
IL151325A0 (en) 2003-04-10
YU63702A (sh) 2006-01-16
KR20020079888A (ko) 2002-10-19
SK11982002A3 (sk) 2003-03-04
US20030176661A1 (en) 2003-09-18
CA2400661A1 (en) 2001-08-30
SE0000597D0 (sv) 2000-02-24
JP2003523213A (ja) 2003-08-05
EE200200473A (et) 2004-02-16
EP1257291A1 (en) 2002-11-20
HUP0300007A3 (en) 2005-11-28
CN1406136A (zh) 2003-03-26
NO20023670D0 (no) 2002-08-02
MXPA02008315A (es) 2002-12-09
RU2002125386A (ru) 2004-03-20
AU3629401A (en) 2001-09-03
RU2268068C2 (ru) 2006-01-20
PL356386A1 (en) 2004-06-28
NO20023670L (no) 2002-08-23

Similar Documents

Publication Publication Date Title
BR0009537A (pt) Composições para tratamento e diagnóstico de câncer de mama e métodos para seu uso
BRPI0510274B8 (pt) uso de um agente para tratar ou prevenir doença celíaca, composição farmacêutica compreendendo dito agente, método de diagnóstico de doença celíaca, ou suscetibilidade à doença celíaca, uso do dito agente para a preparação de um meio de diagnóstico e kit para realizar o dito método de diagnóstico
BR0209177A (pt) Anticorpo especìfico a tumor recombinante e uso do mesmo
AR069903A1 (es) Conjugado anticuerpo- molecula asociada dirigidos a la proteina tirosina quinasa 7 (ptk 7), composicion farmaceutica que lo comprende, acido nucleico, factor de expresion y celula huesped relacionados y su uso para preparar un medicamento util para el tratamiento o prevencion de cancer
BR0110091A (pt) Composições e processos para terapia e diagnóstico de câncer de mama
BR0213224A (pt) agente de ligação especìfico, hibridoma, conjugado, molécula de ácido nucleico, vetor, célula hospedeira, métodos de fabricar um agente de ligação especìfico, de fabricar um anticorpo, de unibir a angiogênese indesejada em um mamìfero e de tratar cáncer em um mamìfero, composição farmacêutica, métodos de modular ou inibir a atividade da angiopoietina-2, de modular pelo menos um dentre a permeabilidade vascular ou o vazamento de plasma em um mamìfero, de tratar doença e de detectar o nìvel de angiopoietina-2 em uma amostra biológica, e, anticorpo
AR046068A1 (es) Anticuerpos de factor tisular y uso de los mismos
BRPI0210886B8 (pt) composto, composição farmacêutica, uso de um composto, e, métodos de geração de imagens, de monitoração do efeito do tratamento de um corpo humano ou animal com uma droga para combater uma condição associada com câncer e de tratamento de câncer ou de uma doença relacionada em um corpo humano ou animal
BR0012069A (pt) Composições e métodos para a terapia e diagnóstico de câncer pulmonar
BR0211546A (pt) Composição farmacêutica e/ou de diagnóstico e uso de microrganismo ou célula
BR0008161A (pt) Uso de uma composição terapêutica para tratamento de uma célula tumoral, composição terapêutica, e kit para tratamento de uma célula tumoral
BR112018015238A2 (pt) conjugado de anticorpo, anticorpo, kit, composição farmacêutica, e, métodos para tratar ou prevenir uma doença ou condição e para diagnosticar uma doença ou condição
BR9508402A (pt) Ligante de união construção de fator de tecido composição farmacêutica kit e uso de um ligante de união
AR012540A1 (es) COMPOSICIoN FARMACÉUTICA LIOFILIZADA DE ANTICUERPOS MONOCLONALES O POLICLONALES, PROCEDIMIENTO PARA SU PRODUCCIoN
BR9912007A (pt) Composições e métodos para terapia e diagnóstico de câncer de próstata
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
WO2004031411A3 (en) Genes and polypeptides relating to human pancreatic cancers
AR006250A1 (es) Compuestos y metodos para la inmunoterapia e inmunodiagnostico del cancer prostatico
BR0209689A (pt) Uso de fragmento de hmg como agente anti-inflamatório
BR0109266A (pt) Composto, composição farmacêutica, método de tratamento de um mamìfero afetado com um câncer, método de liberação de um composto nas células de um mamìfero afetado com um câncer e uso do composto
AR035977A1 (es) Inmunoconjugados de anticuerpos cd44 citotoxicos.
ATE335515T1 (de) Morpholinobildgebung und therapie
ECSP034617A (es) Kit de repinotan
ATE538811T1 (de) Zytotoxizitätsvermittlung von zellen mit hinweisen auf oberflächenexpression von cd44
BR0009608A (pt) Compostos para imunoterapia e diagnóstico de câncer de mama e métodos para sua utilização

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2016 DE 25/08/2009